Nat Commun: A small molecule amyloid inhibitor may be used as a new therapy to treat human cancer

June 30, 2021/Bio Valley BIOON/ --p53 missense mutations can have very serious consequences, and it usually occurs in more than 50% of cancers, and most of the mutations are located in inherent defects.

Image source: https:// a research report entitled "Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function" was published in the international journal Nature Communications.

Previously, researchers found that the use of small-molecule protein mimics may effectively prevent the aggregation and accumulation of proteins related to Alzheimer’s disease and type 2 diabetes; but in this research report, the researchers expanded this protein-based mimic And specifically apply it to the study of cancer-related mutants or p53 aggregates with altered forms

Determination of p53 DBD-ADH-6 interaction interface based on NMR

Image source: Palanikumar, L.

First, the researchers screened a library of protein mimics originally used to target Alzheimer's disease and type 2 diabetes.

Researcher Dr.

Original source:

Palanikumar, L.